A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

HIV Infections Clinical Trial

Official title:

An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00905489
• Other study ID #: 1100.1518
• Secondary ID: 2008-005855-61
• Status: Completed
• Phase: Phase 1
• First received: May 6, 2009
• Last updated: December 2, 2015
• Start date: June 2009
• Est. completion date: September 2012

Study information

• Verified date: December 2015
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesRepublic of Botswana: Ministry of HealthSouth Africa: MCC (Medicines Control Council)United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective is to establish the pharmacokinetic (PK) profile at steady state of nevirapine XR in HIV infected children from >=3 to <18 years of age. This phase I trial is an open-label, multiple dose, non-randomized and cross-over study. Patients who have completed the last visit of the PK trial (visit 7) can enter into an Optional Extension Phase (OEP) until the Investigational New Drug (IND) is withdrawn; until nevirapine XR becomes approved and is available by prescription in a given country; or, the patient enrolls in a compassionate use program. During this OEP, nevirapine XR safety and efficacy information will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Years to 17 Years

Eligibility

Inclusion criteria:

1. Signed and dated written informed consent of a parent or legal guardian prior to admission. Active assent must be given by the patient if the child and/or adolescent is capable of understanding the provided study information.

2. HIV-1 infected males or females >= 3 and < 18 years old.

3. BSA >= 0.58 m2 for patients using BSA to calculate nevirapine IR dose; or BW >= 12.5 kg for patients using BW to calculate nevirapine IR dose at screening visit.

4. Treated with a nevirapine IR based regimen for at least 18 weeks prior to screening visit (Visit 1); no modifications in the ARV background therapy within the last 2 weeks prior to screening.

5. An HIV VL of <50 copies/mL while receiving nevirapine IR at the last measure of VL documented in the medical record obtained within a period of 5 months prior to screening visit.

6. An HIV VL of <50 copies/mL at screening visit.

7. A stable or not decreasing CD4+ cell count according to the investigator's opinion.

8. Acceptable screening laboratory values that indicate adequate baseline organ function according to the opinion of investigator.

9. ALT and AST <= 2.5 X ULN (DAIDS Grade 1).

10. Serum creatinine levels <= 1.3 X ULN (DAIDS Grade 1).

11. Patients able to swallow tablets.

Exclusion criteria:

1. Any AIDS-related or AIDS defining illness that is unresolved or not stable on treatment at least 8 weeks prior to screening visit.

2. Diseases other than HIV infection or conditions that, in the investigator's opinion, would interfere with the study.

3. Patients who have been diagnosed with malignant disease and who are receiving systemic chemotherapy or are anticipated to receive any therapy during their participation in this trial.

4. Use of investigational medications or vaccines within 28 days prior to Visit 1 or during the trial.

5. Use of immunomodulatory drugs within 28 days before Visit 1 or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2).

6. Concomitant protease inhibitor (PI) treatment.

7. Unwillingness to abstain from ingesting substances during the study which may alter plasma drug concentrations by interaction with the cytochrome P450 system (Appendix 10.2).

8. Female patients of childbearing potential who:

• have a positive serum pregnancy test at screening,

• are breast feeding,

• are planning on becoming pregnant,

• are not willing to use double-barrier methods

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Nevirapine Immediate Release (IR)
200 mg Tablet or 50 mg / 5 ml oral suspension
• Nevirapine Extended Release (XR)
200 mg, 300 mg or 400 mg Tablet formulation

Locations

Country	Name	City	State
Botswana	1100.1518.2605 Boehringer Ingelheim Investigational Site	Francistown
Botswana	1100.1518.2601 Boehringer Ingelheim Investigational Site	Gaborone
Botswana	1100.1518.2603 Boehringer Ingelheim Investigational Site	Gaborone
Germany	1100.1518.4902 Boehringer Ingelheim Investigational Site	Berlin
Germany	1100.1518.4901 Boehringer Ingelheim Investigational Site	Frankfurt/Main
Germany	1100.1518.4903 Boehringer Ingelheim Investigational Site	München
South Africa	1100.1518.2702 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	1100.1518.2703 Boehringer Ingelheim Investigational Site	Parow Valley
United States	1100.1518.0002 Boehringer Ingelheim Investigational Site	Philadelphia	Pennsylvania
United States	1100.1518.0001 Boehringer Ingelheim Investigational Site	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Botswana,  Germany,  South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Efficacy: Patients Maintaining a VL < 50 Copies/mL at Last Available Visit	Patients maintaining a viral load < 50 copies/mL at the last available visit	Last available visit, up to 155 weeks	No
Primary	Trough Cpre,N.	Trough Nevirapine concentration immediately prior to the next scheduled dose. Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.; The measure of dispersion presented is the coefficient of variation (%) rather than the geometric coefficient of variation.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	AUCt,ss	Area under the concentration-time curve of the Nevirapine (NVP) in plasma at steady state over the time dosing interval t.; All patients received nevirapine IR for 10 days prior to collection of 12-hour Area Under the Curve (AUC) data. Then, all patients were switched to nevirapine XR for 9 days prior to collection of 24-hour AUC data. The treatments of IR and XR are summarized separately using geometric means and geometric coefficients of variation.; For NVP IR AUC measured over hours: 0,1,2,3,4,8 and 12, For NVP XR AUC measured over hours: 0,1,2,3,4,8,10,12 and 24.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	Cmin,ss (for IR and XR Formulations by Nevirapine XR Dose Group)	Minimum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval t by nevirapine XR dose group Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 21.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	Cmax,ss (for IR and XR Formulations by Nevirapine XR Dose Group)	Maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval t Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	Ratio Cmax,ss/Cmin,ss	Ratio of (maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval t)/(minimum measured concentration of the analyte in plasma at steady state over the time dosing interval t) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	Yes
Secondary	%PTF	Percentage peak-trough Nevirapine fluctuation, % fluctuation (degree of peak to trough fluctuation) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	Tmax,ss	Time from dosing to the maximum concentration of the Nevirapine in plasma at steady state over the time dosing interval t Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.; The standard deviation is actually the coefficient of variation.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	CL/F,ss	Apparent clearance of the Nevirapine in the plasma after extravascular administration at steady-state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	Cavg	Average measured concentration of the Nevirapine in plasma at steady state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.	Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR	No
Secondary	Efficacy: Patients Maintaining a VL < 50 Copies/mL	Patients maintaining a viral load < 50 copies/mL at Day 22.	Day 22	No
Secondary	Efficacy: Patients Maintaining a VL < 400 Copies/mL	Patients maintaining a viral load < 400 copies/mL at Day 22	Day 22	No
Secondary	Change From Baseline in Mean CD4+ Count (Absolute)	Change in mean CD4+ count (absolute) from baseline to Day 22 and from baseline to Week 24.	Baseline, Day 22 and week 24	No
Secondary	Percentage Change From Baseline in Mean CD4+ Count	((Day 22 value-Baseline value)/Baseline value)*100. ((Week 24 value-Baseline value)/Baseline value)*100.	Baseline to day 22 and baseline to week 24	No
Secondary	Efficacy: Patients Maintaining a VL < 50 Copies/mL at Week 24 of Optional Extension Phase	Patients maintaining a viral load < 50 copies/mL at week 24 (approximately 168 days) of Optional Extension Phase (OEP).	week 24	No
Secondary	Efficacy: Patients Maintaining a VL < 400 Copies/mL in Optional Extension Phase	Patients maintaining a viral load < 400 copies/mL at week 24 of the Optional Extension Phase (OEP)	week 24	No

External Links

•   Link